SCHEMBL9923995

SCHEMBL9923995

COC(=O)c1nc2ccc(C)cn2c1C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.74
ALDH1A1 P00352 8/20 0.74
SMN1; SMN2 Q16637 4/20 0.74
RAB9A P51151 3/20 0.74
HSD17B10 Q99714 3/20 0.49
HPGD P15428 2/20 0.47
TSHR P16473 1/20 0.47
NPC1 O15118 2/20 0.44
LMNA P02545 1/20 0.42
ALB P02768 1/20 0.42
CYP3A4 P08684 1/20 0.42
CHRM1 P11229 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA3 P34903 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRK1 P41145 1/20 0.42
HTR2B P41595 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4539838 0.85 ALDH1A1 (0.55) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL16460648 0.85 KDM4E (0.62) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL15900327 0.85 ALDH1A1 (0.55) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL823304 0.84 KDM4E (0.68) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL13696591 0.84 KDM4E (0.68) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL9923994 0.82 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL4331874 0.81 ALDH1A1 (0.51) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL4316016 0.81 SMN1; SMN2 (0.51) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL9893328 0.81 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10
SCHEMBL16461864 0.81 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885ALDH1A1 2230/4885SMN1; SMN2 442/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885ALDH1A1 2230/4885SMN1; SMN2 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.